The Research Institute occupies more than 500,000 square feet of dedicated research space on the Nationwide Children's Hospital campus. We are one of the largest pediatric research centers in the United States and are ranked among the top 10 for National Institutes of Health funding among free-standing children's hospitals
The Centers are structured to support multidisciplinary team science and discovery, enabled by outstanding shared resources. Each is home to 5-15 faculty members working in contiguous space, along with talented staff, graduate students, residents, postdoctoral fellows and other students.
Innovation and commercialization are ingrained in our culture. Scientists are supported by an outstanding cadre of technology commercialization experts. The Office of Technology Commercialization, formed in 2008, already has a remarkable track record of moving discoveries into the marketplace.
Collegiality and collaboration are the bywords at The Research Institute. Our vital role within the Nationwide Children's Hospital enterprise and our academic affiliation with The Ohio State University fosters an affiliative environment that integrates clinical and research resources, encourages dynamic exchange of ideas and supports team science.
Learn about our collaborations »
We are committed to identifying new approaches for the prevention, diagnosis and treatment of childhood diseases, taking research discoveries from the lab to the patient's bedside. Learn about our current studies below:
Gene Transfer Clinical Trial for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)
Phase I/II gene transfer clinical trial for patients with Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) with a study duration of two years and follow-up visits after 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 1 year and 2 years. Read more.
Study for Patients with Duchenne Muscular Dystrophy or Becker Muscular Dystrophy
Patients who are at least 10 years old, have Duchenne Muscular Dystrophy or Becker Muscular Dystrophy, and have a weak heart or a heart device (ex., pacemaker or ICD) are eligible for this non-invasive study, which will collect health information from medical records. Read more.
Infants and Toddlers 9-27 Months Needed for Therapy Study
Infants and young toddlers ages 9-27 months with cerebral palsy who have one side of their body stronger than the other, or those without cerebral palsy and no other motor difficulties, are eligible for this non-invasive, parent-directed therapy study. Read more.